# Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

> **NCT06319170** · PHASE1 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D LLC** · enrollment: 106 (actual)

## Conditions studied

- Schizophrenia, Schizoaffective Disorder

## Interventions

- **DRUG:** Olanzapine Extended Release
- **DRUG:** Olanzapine Immediate Release

## Key facts

- **NCT ID:** NCT06319170
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-28
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-20
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06319170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06319170, "Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06319170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*